| Bioactivity | LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC50 of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity[1]. |
| Invitro | LSD1-IN-21 (compound 5a) shows potent anti-cancer activity with GI50 values of 0.414 and 0.417 µM against HOP-62 and OVCAR-4 cell lines, respectively[1]. |
| Name | LSD1-IN-21 |
| Formula | C24H25N5O2S |
| Molar Mass | 447.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tasneem S, et al. Synthesis, biological evaluation and docking studies of methylene bearing cyanopyrimidine derivatives possessing a hydrazone moiety as potent Lysine specific demethylase-1 (LSD1) inhibitors: A promising anticancer agents. Bioorg Chem. 2022 May 21;126:105885. |